Celgene Exercises Option To Drug Discovery Collaboration With PTC

Anonymous User | Login

Celgene Exercises Option To Drug Discovery Collaboration With PTC

Published: 02-Sep-2009

On advancing drug discovery efforts through PTC's GEMS technology

PTC Therapeutics (PTC) has reported that Celgene has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMST (Gene Expression Modulation by Small-molecules) technology.

Reportedly, in September 2007, Celgene made a $20m equity investment in PTC, which included an option for an exclusive research agreement.

Under the terms of the research collaboration agreement, PTC will receive substantial milestone payments for achieving certain discovery, development, regulatory and commercial objectives.

Stuart Peltz, president and CEO of PTC, said: Celgene's decision to exercise the research option is a wonderful endorsement of our GEMS technology. we look forward to working together to advance this project.

No items to display

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://www.pharmaceutical-business-review.com/news/celgene_exercises_option_to_drug_discovery_collaboration_with_ptc_090902/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

World Courier

Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...

WebWise Learning

Turning Information into Working Knowledge ...

Vetter Pharma International

High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...

Valsynthese

Hazardous Chemistry in Safe Hands ...

USB

Products from Affymetrix ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

No items to display

Suppliers Product News

World Courier CTSCS Depots Provide Dedicated Storage for GMO Products

In response to growing client demand and based on recently-established international biosafety regulations, World Courier has begun rolling out dedicated storage areas for GMO-derived pharmaceutical products throughout its global investigational drug storage network.

World Courier Triples Clinical Trial Storage Capacity Worldwide with Two New Facilities and Client-Driven Expansion

World Courier expands its GMP-compliant Clinical Trial Supply Chain Services (CTSCS) network, facilitating access to growing pharmaceutical markets in Africa and Australia.

World Courier Achieves Coveted GxP-Compliant Status Worldwide with Focus on GDP, Quality Management

With a fully GxP-compliant transport and supply chain system in place, World Courier meets the most demanding industry requirements for managing time- and temperature-sensitive clinical trial materials used in global studies.

Vetter Dedicates New Facility in Suburban Chicago

The new facility will enable collaboration very early in development process

Pharma Supplier Vetter Shares Pride in Consistent Growth and International Success with Distinguished Visitor Minister zu Guttenberg

Economics and Technology Minister visits global leader's headquarters in southern Germany.

Vetter Packages Success with New Facility

Vetter's new secondary packaging operation allows the company to double its production in half the time.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750